Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
•
Non-small cell lung cancer
•
Stage III NSCLC
How do you approach patients with Stage IIIB/C NSCLC with ipsilateral supraclavicular (N3) disease?
Do you initially start with systemic therapy alone or do you proceed directly to chemo-radiation?
Answer from: Medical Oncologist at Academic Institution
Concurrent CT/RT followed by durva if no PD or pneumonitis.
Sign In
or
Register
to read more
12022
Related Questions
How do you approach treatment selection among novel bispecific antibodies and ADCs for patients with EGFR+ NSCLC previously treated with 3rd generation EGFR inhibitors?
When will you select Dato-DXd for patients with EGFR-mutated non-small cell lung cancer?
Given potential long-term CV toxicity concerns with lorlatinib and data suggesting that dose reduction does not compromise efficacy, do you ever recommend initiating and/or maintaining lower-dose lorlatinib in ALK+ NSCLC?
What are your top takeaways in Thoracic Cancers from ASCO 2025?
How do you talk with your patients regarding radiographic expectations on surveillance CT after lung SBRT?
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?
Which patients are you utilizing subcutaneous PD-1/L1 inhibitors instead of the intravenous formulation?
How would you respond to a patient with early-stage resectable NSCLC who has a clinical complete response to neoadjuvant chemo-IO, but subsequently declines surgery, not feeling it's necessary anymore?
When, if at all, do you utilize neoadjuvant chemotherapy alone for resectable, Stage II NSCLC with mutations such as EGFR or ALK?
Would you add immunotherapy to chemotherapy for a patient with metastatic NSCLC, an atypical EGFR mutation, and PD-L1 ≥50% who has progressed on osimertinib?